Maxim Group Begins Coverage on Alimera Sciences (NASDAQ:ALIM)

Maxim Group started coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a research note published on Monday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $10.00 price objective on the biopharmaceutical company’s stock.

Separately, StockNews.com started coverage on shares of Alimera Sciences in a report on Sunday, December 31st. They issued a hold rating for the company.

Alimera Sciences Trading Up 0.8 %

Shares of ALIM opened at $3.90 on Monday. The company has a debt-to-equity ratio of 1.40, a current ratio of 2.39 and a quick ratio of 2.31. Alimera Sciences has a 1 year low of $1.56 and a 1 year high of $4.38. The company has a 50 day simple moving average of $3.77 and a two-hundred day simple moving average of $3.55. The firm has a market cap of $204.17 million, a P/E ratio of -1.81 and a beta of 1.16.

Alimera Sciences (NASDAQ:ALIM) last announced its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.09). Alimera Sciences had a negative net margin of 24.93% and a negative return on equity of 130.90%. The company had revenue of $26.31 million for the quarter, compared to analysts’ expectations of $25.10 million. During the same period last year, the business earned ($0.54) earnings per share. On average, equities analysts expect that Alimera Sciences will post 0.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ALIM. Renaissance Technologies LLC boosted its stake in Alimera Sciences by 2.3% during the second quarter. Renaissance Technologies LLC now owns 127,693 shares of the biopharmaceutical company’s stock worth $698,000 after buying an additional 2,900 shares during the period. Vanguard Group Inc. boosted its stake in Alimera Sciences by 3.7% during the third quarter. Vanguard Group Inc. now owns 146,686 shares of the biopharmaceutical company’s stock worth $455,000 after buying an additional 5,293 shares during the period. Tower Research Capital LLC TRC boosted its stake in Alimera Sciences by 291.8% during the third quarter. Tower Research Capital LLC TRC now owns 12,000 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 8,937 shares during the period. Osaic Holdings Inc. purchased a new stake in Alimera Sciences in the second quarter worth about $34,000. Finally, Millennium Management LLC purchased a new stake in shares of Alimera Sciences during the fourth quarter valued at about $32,000. 99.83% of the stock is owned by hedge funds and other institutional investors.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals. It operates through United States, internationally, and Operating Cost segments. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.